This quarter saw our publication on the STR silencing technology accepted and published in PLOS ONE (see here). It has been exciting to see our work go through the stringent peer-review process at PLOS ONE and we have continued to receive excellent feedback as word of our work spreads further. To this end we have also been preparing for our first in-person conference – PEGS Boston in the week of 2-6th May. With plenty of time to spare we’ve prepared a poster and will also have a 5-minute video available for those attending online. Closer to the time we will announce more details on how to meet us at this event.
We continue to engage with bio-pharma companies both large and small and in particular this quarter we have been establishing closer relationships with contract research organisations (CROs). We’ll be announcing more details soon but we look forward to working closely with a number of CROs to give their customers access to our technology at the very earliest stages of antibody development projects.
We are also looking to broaden access to our technology into new territories outside of the EU and US. Specifically we have been engaging with the Chinese Antibody Society to help launch mAbsolve and our STR silencing technology into the Chinese market. We hope to be providing more information about this very soon!